Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Pilotundersøgelse af effektiviteten og sikkerheden af ​​OPTILENE® SILVER MESH ELASTIC til forebyggelse af kirurgisk infektion (SSI) og incisionsbrok (IH) (SSIHLVER)

5. november 2026 opdateret af: Aesculap AG

Prospektiv beskrivende multicenterpilotundersøgelse af effektiviteten og sikkerheden af ​​Optilene® Silver Mesh Elastic til forebyggelse af kirurgisk infektion på stedet (SSI) og incisionsbrok (IH)

The aim of the study is to describe the effectiveness of Optilene® Silver Mesh Elastic on prevention of surgical site infection (SSI) at 6 months follow-up in patients undergoing urgent laparotomy by collecting clinical data on the SSI rates, IH rates and overall clinical performance of Optilene® Silver Mesh Elastic used for the prevention of incisional hernia as prophylactic mesh in patients that require urgent median laparotomy in clinical routine.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

110

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Irene Fita Esteban
  • Telefonnummer: +34609054401
  • E-mail: info@bbraun.com

Undersøgelse Kontakt Backup

  • Navn: José Manuel Molina Villar
  • Telefonnummer: +34697502623
  • E-mail: info@bbraun.com

Studiesteder

      • Badalona, Spanien, 08916
        • Hospital Universitari Germans Tries i Pujol
        • Kontakt:
          • Joan Francesc Julián, Dr.
        • Ledende efterforsker:
          • Joan Francesc Julián, Dr.
      • Badalona, Spanien
        • Hospital Municipal Badalona
        • Kontakt:
          • Jorge Marroquin, Dr.
        • Ledende efterforsker:
          • Jorge Marroquin, Dr.
      • Calella, Spanien, 08370
        • Hospital Comarcal Sant Jaume de Calella
        • Kontakt:
          • Paqui Vasco, Dr.
        • Ledende efterforsker:
          • Paqui Vasco, Dr.
      • Mataró, Spanien, 08304
        • Hospital de Mataró
        • Kontakt:
          • Berhanu Chimdi, Dr.
        • Ledende efterforsker:
          • Berhanu Chimdi, Dr.
      • Santa Coloma de Gramenet, Spanien, 08923
        • Hospital Fundació Esperit Sant
        • Kontakt:
          • Daniel Troyano Escribano, Dr.
        • Ledende efterforsker:
          • Daniel Troyano Escribano, Dr.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

High-risk patients according to the professional criteria (such as but not limited to: age, nutrition, body mass index, comorbidities, etc.) who are undergoing prophylactic mesh implantation to avoid surgical site infection after an emergency or urgent intra-abdominal laparotomy.

Beskrivelse

Inclusion Criteria:

  • Adult patients (18 years or older)
  • Surgical procedure requiring urgent, primary median laparotomy, which are classified as "Class III/Contaminated" or "Class IV/Dirty-Infected" regarding the CDC classification.

These include but are not limited to:

  • Vascular surgery

  • Colon and rectum

  • Hepatobiliary

  • Gastrointestinal

  • Gynecology

  • Urology

  • Abdominal Aortic Aneurysm (AAA) repair

  • Right hemicolectomy

  • Left hemicolectomy

  • Sigmoidectomy

  • Anterior resection

  • Abdominoperineal amputation

  • Exploratory laparotomy

  • Cholecystectomy

  • Cholecystectomy and choledocotomy

    • Written informed consent

Exclusion Criteria:

  • Pregnancy
  • Breast feeding
  • Patients < 18 years old or patients who are still in the growth phase
  • Contaminated and infected areas
  • Hypersensitivity to silver
  • Direct contact with the viscera
  • Previous allergic reactions to components of the device
  • Patient with previous laparotomy
  • Transverse laparotomy
  • Patients with previous hernia repair
  • Simultaneous participation in another investigational clinical trial (drug or medical studies)
  • Patients with active oncologic treatment (chemo and radiotherapy)
  • Underlying autoimmune disease
  • Recent cardiovascular complication
  • Gynecology surgery
  • Urology surgery
  • Vascular surgery

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Optilene® Silver Mesh Elastic

Prophylactic mesh in high-risk patients

Prevention of incisional hernia after a prophylactic mesh in high-risk patients

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Surgical Site Infection (SSI) A2/A3 rate
Tidsramme: at 6 months follow-up

SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources. Centers for Disease Control and Prevention Surgical Site Infection (SSI) Classification System differentiates Superficial SSI (A1), Deep Incisional SSI (A2) and Infection with involvement of organs/body cavities (A3). Only cases of A2 and A3 are considered for the Primary Outcome and are compared to rates from reference literature

at 6 months follow-up

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Cumulative rate of of postoperative complications during the study period
Tidsramme: at discharge (up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up

Numbers of all postoperative complications such as mortality, burst abdomen, bowel obstruction, bulging, necrosis, fistula, wound dehiscence, hematoma, seroma, peritonitis are added to the overall complication rate that is observed over the postoperative course

at discharge (up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up
Cumulative Surgical Site Infection (SSI) A2/A3 rate during the study period
Tidsramme: at 1 month, 1 year and 2 year follow-up.

Number of the Surgical Site Infection (SSI) (only A2 and A3) rate at every follow-up

at 1 month, 1 year and 2 year follow-up.
Incisional hernia (IH) rate during the study period
Tidsramme: repeatedly at 6 months, 1 year and 2 year follow-up.

Incisional hernia (IH) is a protrusion of tissue that forms at the site of a healing surgical scar. Incisional hernia refers to abdominal wall hernia at the site of a previous surgical incision.

repeatedly at 6 months, 1 year and 2 year follow-up.
Length of hospital stay
Tidsramme: at discharge (approximately up to 10 days after surgery)

Number of days the patient has to stay in hospital after the surgery

at discharge (approximately up to 10 days after surgery)
Development of Pain: Visual Analogue Scale (VAS)
Tidsramme: at discharge (approximately up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up, using the VAS score

This parameter will be noted using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "heavy pain".

at discharge (approximately up to 10 days after surgery), 1 month, 6 months, 1 year and 2 year follow-up, using the VAS score
Time to return to work
Tidsramme: at all postoperative examinations with a single value for each individual patient

The number of days needed to return to work after the surgery of the individual patient is documented

at all postoperative examinations with a single value for each individual patient
Handling of the Optilene® Silver Mesh Elastic
Tidsramme: intraoperatively

The handling will be evaluated using a questionnaire (Likert-type scale) with the dimensions Tensile Strength, Absence of memory effect, Elasticity, Stiffness, Surface weight, Thickness, Ease of being fixed with suture, Ease of package extraction as well as an overall opinion in five evaluation levels (excellent=1, very good=2, good=3, satisfied=4, poor=5)

intraoperatively

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Daniel Troyano Escribano, Dr., Fundació Hospital de l'Esperit Sant

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. februar 2027

Primær færdiggørelse (Anslået)

1. marts 2028

Studieafslutning (Anslået)

1. september 2029

Datoer for studieregistrering

Først indsendt

7. august 2024

Først indsendt, der opfyldte QC-kriterier

7. august 2024

Først opslået (Faktiske)

9. august 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • AAG-G-H-2126

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .